FDA Ethics Act of 2022

Hozzl · 2022-12-29T12:33:50Z

Explore the details of House Bill 8828 FDA Ethics Act of 2022 currently in Congress. Get insights into its purpose, current status, sponsors, and potential impact on Health. Stay informed on legislative developments.

12/29/2022, 12:33 PM

Summary of Bill HR 8828

Bill 117 HR 8828, also known as the FDA Ethics Act of 2022, is a piece of legislation introduced in the US Congress. The main purpose of this bill is to establish ethical guidelines and standards for employees of the Food and Drug Administration (FDA).

The bill outlines various provisions aimed at promoting transparency, accountability, and integrity within the FDA. It requires FDA employees to adhere to a code of ethics that prohibits conflicts of interest, bribery, and other unethical behavior. The bill also establishes a process for reporting and investigating ethical violations within the agency.

Additionally, the FDA Ethics Act of 2022 requires FDA employees to disclose any financial interests or relationships that may pose a conflict of interest. This is intended to prevent undue influence from outside parties and ensure that FDA decisions are based on scientific evidence and public health considerations. Overall, the FDA Ethics Act of 2022 seeks to strengthen the ethical standards and integrity of the FDA, ultimately enhancing public trust in the agency and its regulatory decisions.

Congressional Summary of HR 8828

FDA Ethics Act of 2022

This bill establishes several requirements for entities that contract with the Food and Drug Administration (FDA) relating to conflicts of interest, including requiring contractors to disclose conflicts of interest on an ongoing basis and prohibiting the FDA from hiring consultants who simultaneously provide services to drug manufacturers or other entities that are regulated by the FDA.

Read the Full Bill

Formatted Text PDF Formatted XML

Current Status of Bill HR 8828

Bill HR 8828 is currently in the status of Bill Introduced since September 14, 2022. Bill HR 8828 was introduced during Congress 117 and was introduced to the House on September 14, 2022. Bill HR 8828's most recent activity was Referred to the Subcommittee on Health. as of September 15, 2022